Hi All,
As promised my question and response from Imugene regarding the ongoing HerVaxx trials. After initial disappointment of no response 20/11/22. I tired again after Paul Hoppers commitment to improve shareholder communication 06/01/23. And pleasing to see Paul has made good on his commitment with someone from within Imugene responding 12/01/2023, which has buoyed my confidence in management (ie they do what they say). (Please refer to bottom on post for correspondence)
Additionally rereading the investor presentation 09/01/2023. The next information drop due is a trial in progress poster NextHerizon (page 35). (Something I missed at the time).
Does anyone have any experience as to what is included on a trial in progress poster?
I assume they must be releasing some initial data? Or what else are they going to talk about?
Not to get overly excited; But if it is data, and the data is good, this could finally be the catalyst for re rate which many of us have been longing for.
·First patient was dosed 08/09/22 (call it 5 months ago).
·The trial is approaching about half way through (12 – 18 months)
·As per the initial Herizon trial
·Antibody response happens within the first 2 months of receiving Hervaxx
·NextHerizon is at double dosage of Hervaxx to Herizon. So, antibody response should be more apparent
·Deviation in overall survival should become apparent within the first 3 months of treatment
“ My Email
Referencing the last investor presentation released to the market 15/11/2022
1.NeuHERIZON is no longer listed on the poster (page 5). Are you able to confirm if this study is no longer going ahead?
2.NeoHERIZON is listed on the poster (page 5), but on the Milestone poster (page 28) NeoHERIZON is not mentioned in the forward guidance of milestones that are likely to be achieved. Are you able to confirm if this study is still planned to proceed? If so, are you able to provide any guidance on when we may see the trial commence?
3.Lastly, given the NeoHERIZON trial was flagged on 01/09/2021, a supply agreement with Merck (Germany) was announced 16/11/2021 (which as I understand it is still valid?), the NextHERIZON trial commenced 08/09/2022 are you able to disclose any further detail as to why additional time is needed before being able to commence the NeoHERIZON trial?
Yours faithfully
“
“ Response
NeuHerizon was a study for exploratory biomarkers however, it made economic and efficient sense to build it into the neoHERIZON study.
As the neoHerizon study is now made more robust, we needed to find the right countries for the standard of care and the best gastric oncologist to conduct this study as it is highly technical. I am happy to report that we have found a key opinion leader to lead this study and plans are well advanced to commence in 2023.
Best regards,
“
(20min delay)